ESPEN-EASO Sarcopenic Obesity Diagnostic Criteria Application in COPD Patients and Its Relation to Diaphragm Function and Rehabilitation Outcomes: An Observational Study

What this Trial Is About

Researchers are investigating the prevalence of sarcopenic obesity among patients with chronic obstructive pulmonary disease (COPD) using recently defined ESPEN/EASO diagnostic criteria. Sarcopenic obesity is a condition characterized by excess fat mass and reduced muscle mass and function. The study aims to understand how sarcopenic obesity affects respiratory function, disease severity, exercise performance, quality of life, and dyspnea levels in COPD patients compared to those with normal weight or sarcopenia alone. This observational study involves assessing COPD patients according to their body mass index (BMI) categories: normal weight, overweight, and obese. Patients undergo evaluations including spirometry to measure lung function, ultrasound to assess diaphragm thickness and movement, and the six-minute walk test (6-MWT) to gauge exercise capacity. Questionnaires measuring dyspnea and quality of life are also administered. The study applies the ESPEN/EASO criteria to diagnose sarcopenic obesity and calculate its prevalence within the COPD population. Participants are monitored from enrollment through a 4-week period during which diagnosis and calculation of sarcopenic obesity occur. Researchers collect data on respiratory function, physical performance, dyspnea, and quality of life. The study emphasizes early diagnosis to enable targeted nutritional and rehabilitation strategies. No investigational therapies are administered; this is an observational study focusing on detailed assessments and correlations within the COPD patient group.

Prevalence of Sarcopenic Obesity in COPD